RJA
APLT

Raymond James & Associates’s Applied Therapeutics APLT Stock Holding History

Raymond James & Associates’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,658
Closed -$72.5K – 3964
2024
Q1 		$72.5K Buy
+10,658
New +$47.8K ﹤0.01% 3770

Other funds holding APLT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James & Associates's APLT Position: Q2 2024 in Review

Raymond James & Associates sold out of Applied Therapeutics (APLT) in Q2 2024, closing a stake of 10,658 shares — an estimated $72.5K sold.

Raymond James & Associates first reported a position in APLT in Q1 2024 and held it in 1 quarter. The position peaked at $72.5K in Q1 2024. 94 funds tracked by Wall St. Rank hold APLT as of Q2 2024.

  • Raymond James & Associates reported no remaining Applied Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Raymond James & Associates sold 10,658 Applied Therapeutics shares in Q2 2024, an estimated $72.5K.
  • Raymond James & Associates first reported a position in Applied Therapeutics in Q1 2024 and held it in 1 quarter.
  • Raymond James & Associates's Applied Therapeutics position peaked at $72.5K in Q1 2024.
  • 94 funds tracked by Wall St. Rank held Applied Therapeutics as of Q2 2024.

Based on Raymond James & Associates's 13F filing for Q2 2024, filed 19 Jul 2024.